Grifols (NASDAQ:GRFS) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Grifols (NASDAQ:GRFS) from a hold rating to a buy rating in a research report released on Friday morning.

Separately, Morgan Stanley started coverage on shares of Grifols in a research report on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Trading Down 0.2%

Shares of NASDAQ:GRFS opened at $8.11 on Friday. Grifols has a 52 week low of $5.79 and a 52 week high of $9.96. The company’s 50 day moving average is $7.31 and its two-hundred day moving average is $7.61. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The company has a market cap of $5.58 billion, a PE ratio of 6.93 and a beta of 0.44.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its position in shares of Grifols by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock valued at $29,948,000 after buying an additional 80,507 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Grifols in the 1st quarter valued at $184,000. Royal Bank of Canada grew its position in shares of Grifols by 21.7% in the 1st quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company’s stock valued at $3,461,000 after buying an additional 86,768 shares during the last quarter. Vident Advisory LLC grew its position in shares of Grifols by 134.5% in the 1st quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company’s stock valued at $495,000 after buying an additional 39,902 shares during the last quarter. Finally, Groupe la Francaise purchased a new position in shares of Grifols in the 1st quarter valued at $1,699,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.